New Malaria Drug Formulation for Infants Approved, Offering Hope for Reduced Child Mortality in Africa
Table of Contents
A new formulation of artemether-lumefantrine, designed to be soluble in breast milk and palatable for infants, has been developed and approved, offering a possibly life-saving advancement in the fight against malaria in Africa. The drug aims to address the high burden of malaria among children under five, who accounted for nearly 76% of malaria deaths in Africa in 2023.
The Challenge of Malaria in Africa
Malaria remains a notable public health crisis in Africa.According to the World Health Association (WHO), in 2023, there were 263 million cases of malaria globally, resulting in an estimated 597,000 deaths across 83 countries. A staggering 94% of thes cases (246 million) and 95% of deaths (569,000) occured in Africa. Children under five are particularly vulnerable, highlighting the urgent need for effective and accessible treatments.
A New Formulation for Infants
The new artemether-lumefantrine formulation, developed by Novartis and Medicines for Malaria Venture (MMV),addresses a critical gap in malaria treatment for infants. Traditional malaria medications can be challenging for young children to swallow, leading to incorrect dosages and reduced efficacy.
this new formulation is designed to be:
Soluble in breast milk: Allows for easy administration to infants.
Sweet-tasting: Improves palatability and encourages complete consumption of the dose.
Safe and effective: Offers a well-established treatment in a more accessible format.
The formulation has been validated by Swiss authorities, with rapid approvals anticipated in participating African countries. According to the Africa CDC, this represents a safe, effective, and adapted option for infants.
Pamafrica Consortium and Drug Growth
The development of this new formulation is a result of the collaborative efforts within the Pamafrica consortium. This initiative highlights the importance of partnerships between pharmaceutical companies, research organizations, and public health agencies in tackling global health challenges.
Key Takeaways
Malaria disproportionately affects children under five in africa, accounting for the majority of deaths.
A new, infant-pleasant formulation of artemether-lumefantrine has been approved, offering a more accessible and effective treatment option.
the drug is soluble in breast milk and has a sweet taste, improving administration and compliance.
* The development of this formulation is a result of collaboration between Novartis, MMV, and the Pamafrica consortium.
Looking Ahead
The widespread adoption of this new malaria drug formulation has the potential to significantly reduce child mortality rates in Africa. Continued efforts to improve access to diagnosis, treatment, and preventative measures, such as insecticide-treated bed nets and indoor residual spraying, will be crucial in achieving the goal of a malaria-free Africa.